Show simple item record

dc.contributor.authorHall, Matthew D.
dc.contributor.authorAnderson, James M.
dc.contributor.authorSchiffer, Celia A.
dc.contributor.authorConley, Anthony J.
dc.contributor.authorDavis, Mindy I.
dc.date2022-08-11T08:08:10.000
dc.date.accessioned2022-08-23T15:45:05Z
dc.date.available2022-08-23T15:45:05Z
dc.date.issued2021-06-10
dc.date.submitted2021-06-14
dc.identifier.citation<p>Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, Campbell EA, Corbett KS, Carter K, Cherry S, Chiang L, Cihlar T, de Wit E, Denison M, Disney M, Fletcher CV, Ford-Scheimer SL, Götte M, Grossman AC, Hayden FG, Hazuda DJ, Lanteri CA, Marston H, Mesecar AD, Moore S, Nwankwo JO, O'Rear J, Painter G, Saikatendu KS, Schiffer CA, Sheahan TP, Shi PY, Smyth HD, Sofia MJ, Weetall M, Weller SK, Whitley R, Fauci AS, Austin CP, Collins FS, Conley AJ, Davis MI. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. J Infect Dis. 2021 Jun 10:jiab305. doi: 10.1093/infdis/jiab305. Epub ahead of print. PMID: 34111271. <a href="https://doi.org/10.1093/infdis/jiab305">Link to article on publisher's site</a></p>
dc.identifier.issn0022-1899 (Linking)
dc.identifier.doi10.1093/infdis/jiab305
dc.identifier.pmid34111271
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27452
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractThe NIH Virtual SARS-CoV-2 Antiviral Summit, held on November 6, 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for COVID-19, including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss SARS-CoV-2 targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34111271&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsThis article is a work of the United States government. Such works are not entitled to domestic copyright protection under U.S. law and are therefore in the public domain.
dc.subjectSARS-CoV-2
dc.subjectantiviral therapeutics
dc.subjectemerging modalities
dc.subjectpreclinical
dc.subjectproteases
dc.subjectviral replication machinery
dc.subjectImmunology of Infectious Disease
dc.subjectImmunotherapy
dc.subjectInfectious Disease
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectMicrobiology
dc.subjectPharmaceutics and Drug Design
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleReport of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
dc.typeAccepted Manuscript
dc.source.journaltitleThe Journal of infectious diseases
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1255&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/252
dc.identifier.contextkey23348829
refterms.dateFOA2022-08-23T15:45:05Z
html.description.abstract<p>The NIH Virtual SARS-CoV-2 Antiviral Summit, held on November 6, 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for COVID-19, including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss SARS-CoV-2 targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.</p>
dc.identifier.submissionpathcovid19/252
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology


Files in this item

Thumbnail
Name:
jiab305_2_.pdf
Size:
1.328Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record